Foghorn Therapeutics (FHTX) Revenue (2020 - 2026)
Foghorn Therapeutics' quarterly Revenue came in at $3.3 million in Q1 2026, down 45.11% year-on-year from $6.0 million in Q1 2025, and down 64.67% quarter-over-quarter from $9.2 million in Q4 2025.
Foghorn Therapeutics has reported Revenue for 7 years, with the latest figure at $3.3 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue fell 45.11% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $28.2 million (up 20.08% YoY), and the FY2025 full-year result was $30.9 million, up 36.75% from the prior year.
- Revenue for Q1 2026 stood at $3.3 million, down from $9.2 million in the prior quarter.
- The five-year high for Revenue was $17.5 million in Q3 2023, with the low at $2.9 million in Q4 2024.
- Average Revenue over 5 years is $6.5 million, with a median of $5.8 million recorded in 2023.
- Year-over-year, Revenue surged 16080.49% in 2022 and slumped 55.33% in 2024.
- Tracing FHTX's Revenue over 5 years: stood at $4.2 million in 2022, then jumped by 37.88% to $5.8 million in 2023, then slumped by 50.49% to $2.9 million in 2024, then jumped by 223.77% to $9.2 million in 2025, then tumbled by 64.67% to $3.3 million in 2026.
- The last three Revenue figures came in at $3.3 million (Q1 2026), $9.2 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - | 3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 9.25 Mn |
| Sep 30, 2025 | 8.15 Mn |
| Jun 30, 2025 | 7.56 Mn |
| Mar 31, 2025 | 5.95 Mn |
| Dec 31, 2024 | 2.86 Mn |
| Sep 30, 2024 | 7.81 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 5.05 Mn |
| Dec 31, 2023 | 5.77 Mn |
| Sep 30, 2023 | 17.48 Mn |
| Jun 30, 2023 | 5.60 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 4.18 Mn |
| Sep 30, 2022 | 6.63 Mn |
| Jun 30, 2022 | 4.49 Mn |
| Mar 31, 2022 | 3.92 Mn |
| Dec 31, 2021 | 713,000.00 |
| Sep 30, 2021 | 41,000.00 |
| Jun 30, 2021 | 279,000.00 |
| Mar 31, 2021 | 286,000.00 |
| Dec 31, 2020 | 251,000.00 |
| Sep 30, 2020 | 179,000.00 |